GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
GAiT just sent an iPSC Quality Round Update to Participants from 18 sites across 11 countries informing them of the status of Quality re-tests, the data workshop, and manuscript preparation.
Kyoto University seeks government approval to conduct a clinical trial of transplanted cartilage made from iPS cells -
Kyoto Univ. seeks to use stem cells for damaged knee joint treatment
Kyoto University says it has asked for government approval to conduct a clinical trial of transplanting cartilage made from induced pluripotent stem c...
We are looking for an associate scientist to work with #geneediting and #genomics on the NYSCF Global Stem Cell Array-- our automated system for #stemcell derivation, gene editing, and downstream differentiations. Learn more and apply here: http://bit.ly/33LS3Eg #STEMjobs
Do you want to #study & #work in the field of #RegenerativeMedicine? APPLY NOW to the
@wellcometrust funded "Advanced Therapies for Regenerative Medicine" course at the CSCRM
@KCLWP @KCLResDevHealth @kcldo1thing @kclwim @KCL_MRCDTP
GAiT's new Director Annelise Bennaceur Griscelli (@Inserm) will be attending the RESTORE meeting (Berlin) next week & will be discussing GAiT's efforts to standardize iPSC manufacture for allogeneic therapeutic development. More on RESTORE here: https://apnews.com/f9aca5d5fb2fa4100b29480d221e5658
If you are a Quality Round Participant and would like to discuss the Quality Round directly with GAiT before the planned conference calls, you can set up a direct meeting by emailing email@example.com
iPSC Quality Round 2019: material for secondary testing is being dispatched Monday 18th November 2019.
The key to the #commercialization journey is actually in developing relationships with stakeholders through an understanding of priorities, rather than trying to be an expert in all areas. #regenmed #commercialization @MTPConnect_AUS
It was useful to catch up with @BlueRockTx, @CGTCatapult and @CCRM_ca at the @ISSCR meeting in Toronto today. Three important participants in the iPSC #Quality Round 2019.